Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

X. Xiaoguang



Author of

  • +

    P2.07 - Poster Session/ Small Cell Lung Cancer (ID 222)

    • Event: WCLC 2015
    • Type: Poster
    • Track: Small Cell Lung Cancer
    • Presentations: 1
    • +

      P2.07-004 - The Relationship between UGT1A1 Gene Polymorphism and Irinotecan Effect on ED-SCLC (ID 301)

      09:30 - 09:30  |  Author(s): X. Xiaoguang

      • Abstract
      • Slides

      Background:
      NCCN recommends IP program as a first-line chemotherapy of ED-SCLC.Several clinical study conducted in colorectal cancer showed that the polymorphism of UGT1A1*28 gene can evaluate the risk of severe neutropenia and diarrhea occurred in patients receiving irinotecan chemotherapy. The purpose of this research is to analyze the distribution of UGT1A1 gene polymorphisms in Chinese Han patients with ED-SCLC，and to evaluate correlations between UGT1A1 gene polymorphisms and toxicity and efficacy of irinotecan in patients with ED-SCLC.

      Methods:
      Analysis of UGT1A1*28 and UGT1A1*6 gene polymorphisms were performed by peripheral blood gene sequencing. From June 2011 to Nov 2013, 67 cases admitted to hospital with ED-SCLC treated by irinotecan(CPT-11) based regimen were enrolled in this study. We observe the relationship of PFS , OS and AEs between different genotypes.

      Results:
      Figure 1 figure 1 the PFS and different gene type Figure 2 figure 2 the OS and different gene type The median PFS of wild type UGT1A1*28 (TA6/6) and mutant (TA6/7) was 9.9 months and 10 months respectively; the median PFS of wild type UGT1A1*6 (G/G) and UGT1A1*6 mutant (G/A) was 9.7 months and 9.9 months respectively. The median OS of wild type UGT1A1*28 (TA6/6) and mutant (TA6/7) was 13.9 months and 14.5 months respectively; the median OS of wild type UGT1A1*6 (G/G) and UGT1A1*6 mutant (G/A) was 13.8 months and 14.1 months respectively. No significant difference of PFS and OS was observed between different genotypes(p>0.05). The incidence of grade 3 and 4 delayed diarrhea and neutropenia in patients carrying UGT1A1*6 G/A was higher than that in the WT genotype(36.4% vs. 6.6% p<0.05; 27.2% vs. 4.4% p<0.05 respectively); The patients simultaneously carrying UGT1A1*28 TA6/7 and UGT1A1*6 G/A were prone to suffering 3 and 4 delayed diarrhea and neutropenia.





      Conclusion:
      Although UGT1A1 polymorphisms failed to predict the efficacy of CPT-11 in ED-SCLC, the prediction of adverse effect may worth attention.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.